- Home
- IDYA vs TTMI Comparison
IDYA vs TTMI Comparison
Compare IDYA & TTMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- TTMI
- Stock Information
- Founded
- IDYA 2015
- TTMI 1978
- Country
- IDYA United States
- TTMI United States
- Employees
- IDYA N/A
- TTMI N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- TTMI Electrical Products
- Sector
- IDYA Health Care
- TTMI Technology
- Exchange
- IDYA Nasdaq
- TTMI Nasdaq
- Market Cap
- IDYA 1.9B
- TTMI 4.6B
- IPO Year
- IDYA 2019
- TTMI 2000
- Fundamental
- Price
- IDYA $25.35
- TTMI $48.73
- Analyst Decision
- IDYA Strong Buy
- TTMI Strong Buy
- Analyst Count
- IDYA 13
- TTMI 5
- Target Price
- IDYA $51.36
- TTMI $41.00
- AVG Volume (30 Days)
- IDYA 955.1K
- TTMI 2.5M
- Earning Date
- IDYA 08-08-2025
- TTMI 07-30-2025
- Dividend Yield
- IDYA N/A
- TTMI N/A
- EPS Growth
- IDYA N/A
- TTMI N/A
- EPS
- IDYA N/A
- TTMI 0.75
- Revenue
- IDYA $7,000,000.00
- TTMI $2,521,308,000.00
- Revenue This Year
- IDYA $115.83
- TTMI $11.55
- Revenue Next Year
- IDYA $252.50
- TTMI $5.54
- P/E Ratio
- IDYA N/A
- TTMI $65.18
- Revenue Growth
- IDYA N/A
- TTMI 11.65
- 52 Week Low
- IDYA $13.45
- TTMI $15.78
- 52 Week High
- IDYA $44.42
- TTMI $50.43
- Technical
- Relative Strength Index (RSI)
- IDYA 68.62
- TTMI 68.70
- Support Level
- IDYA $24.46
- TTMI $44.26
- Resistance Level
- IDYA $26.15
- TTMI $48.59
- Average True Range (ATR)
- IDYA 1.06
- TTMI 2.01
- MACD
- IDYA 0.29
- TTMI -0.12
- Stochastic Oscillator
- IDYA 83.23
- TTMI 77.12
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About TTMI TTM Technologies Inc.
TTM Technologies Inc manufactures technology solutions, including mission systems, radio frequency (RF) components/RF microwave/microelectronic assemblies, quick-turn and technologically printed circuit boards (PCB). The company is based in the United States and derives roughly half of its revenue domestically. It organizes itself into two segments: printed circuit boards and RF&S Components. The printed circuit boards segment, which contributes the majority of revenue, offers a range of printed circuit boards as well as layout design and simulation, and testing services. TTM Technologies' products are used in manufacturing, networking, telecommunications, computing, aerospace, and medical fields.